Downregulation of Keap1 contributes to poor prognosis and Axitinib resistance of renal cell carcinoma via upregulation of Nrf2 expression

被引:21
作者
Huang, Haipeng [1 ]
Wu, Yunhong [2 ]
Fu, Weijin [3 ]
Wang, Xiaoming [1 ]
Zhou, Liquan [1 ]
Xu, Xiaolong [1 ]
Huang, Fu [1 ]
Wu, Yi [4 ]
机构
[1] Guangxi Med Univ, Affiliated Hosp 2, Dept Urol, Nanning 530007, Guangxi, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 2, Med Records Informat Management Div, Nanning 530007, Guangxi, Peoples R China
[3] Guangxi Med Univ, Affiliated Hosp 1, Dept Urol, Nanning 530021, Guangxi, Peoples R China
[4] Guangxi Med Univ, Affiliated Hosp 2, Dept Dermatol, 166 Daxuedong Rd, Nanning 530007, Guangxi, Peoples R China
关键词
Kelch-like ECH-associated protein 1; nuclear factor erythroid 2-related factor 2; prognosis; Axitinib resistance; renal cell carcinoma; SIGNALING PATHWAY; TARGETED THERAPY; OXIDATIVE STRESS; GENE-EXPRESSION; ACTIVATES NRF2; SENSOR KEAP1; DUAL ROLES; E3; LIGASE; INHIBITION; MUTATIONS;
D O I
10.3892/ijmm.2019.4134
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Kelch-like ECH-associated protein 1 (Keap1)/nuclear factor erythroid 2-related factor 2 (Nrf2) signaling has a protective effect on normal cells. A number of previous studies demonstrated that Keap1/Nrf2 signaling is associated with drug resistance in numerous tumors. The aim of the present study was to investigate the roles of Keap1 in renal cell carcinoma (RCC) and its effect on sensitivity to chemotherapy. Reverse transcription-quantitative polymerase chain reaction was used to detect the mRNA expression of Keap1 in 45 cases of RCC tumors and adjacent normal tissues. A total of five randomly selected patients with RCC, five RCC cell lines and normal renal tubular cells were examined to detect the protein and mRNA expressions of Keap1. The 5-year survival rate was analyzed by Kaplan-Meier analysis. The cell viability was assessed by a Cell Counting kit-8 assay. The cell apoptosis and reactive oxygen species (ROS) were determined by flow cytometry. The expressions of associated proteins were determined by western blot analysis. It was identified that in RCC tissues and RCC cell lines, the expression of Keap1 was downregulated, which was considered to be associated with poor prognosis. In total, 1 mu M Axitinib significantly decreased cell viability, promoted ROS release and induced cell apoptosis in ACHN cells. Silencing Keap1 was able to reverse the inhibitory effect of Axitinib and enhance the protein expressions of Nrf2, NAD(P)H dehydrogenase [quinone] 1 and heme oxygenase 1. However, silencing Nrf2 increased the cell sensitivity to Axitinib. Under Axitinib condition, overexpressing Nrf2 was able to increase cell viability; however, overexpressing Keap1 resulted in an opposite effect. Keap1 serves as a tumor suppressor; its low expression was associated with poor prognosis and a decreased sensitivity of RCC cells to Axitinib. A possible mechanism underlying Axitinib resistance may involve Nrf2 overexpression.
引用
收藏
页码:2044 / 2054
页数:11
相关论文
共 63 条
[1]   Aberrant Keap1 methylation in breast cancer and association with clinicopathological features [J].
Barbano, Raffaela ;
Muscarella, Lucia Anna ;
Pasculli, Barbara ;
Valori, Vanna Maria ;
Fontana, Andrea ;
Coco, Michelina ;
la Torre, Annamaria ;
Balsamo, Teresa ;
Poeta, Maria Luana ;
Marangi, Giovanni Francesco ;
Maiello, Evaristo ;
Castelvetere, Marina ;
Pellegrini, Fabio ;
Murgo, Roberto ;
Fazio, Vito Michele ;
Parrella, Paola .
EPIGENETICS, 2013, 8 (01) :105-112
[2]   Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non-small-cell lung cancer [J].
Bondarenko, Igor M. ;
Ingrosso, Antonella ;
Bycott, Paul ;
Kim, Sinil ;
Cebotaru, Cristina L. .
BMC CANCER, 2015, 15
[3]   Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials [J].
Coppin, Chris ;
Kollmannsberger, Christian ;
Le, Lyly ;
Porzsolt, Franz ;
Wilt, Timothy J. .
BJU INTERNATIONAL, 2011, 108 (10) :1556-1563
[4]   Mitochondrial "power" drives tamoxifen resistance: NQO1 and GCLC are new therapeutic targets in breast cancer [J].
Fiorillo, Marco ;
Sotgia, Federica ;
Sisci, Diego ;
Cappello, Anna Rita ;
Lisanti, Michael P. .
ONCOTARGET, 2017, 8 (12) :20309-20327
[5]   ClinicalandPathological Characteristics of KEAP1- and NFE2L2-Mutated Non-Small Cell Lung Carcinoma (NSCLC) [J].
Frank, Rieke ;
Scheffler, Matthias ;
Merkelbach-Bruse, Sabine ;
Ihle, Michaela A. ;
Kron, Anna ;
Rauer, Michael ;
Ueckeroth, Frank ;
Koenig, Katharina ;
Michels, Sebastian ;
Fischer, Rieke ;
Eisert, Anna ;
Fassunke, Jana ;
Heydt, Carina ;
Serke, Monika ;
Ko, Yon-Dschun ;
Gerigk, Ulrich ;
Geist, Thomas ;
Kaminsky, Britta ;
Heukamp, Lukas C. ;
Clement-Ziza, Mathieu ;
Buettner, Reinhard ;
Wolf, Juergen .
CLINICAL CANCER RESEARCH, 2018, 24 (13) :3087-3096
[6]  
Galloway DC, 1997, BIOCHEM J, V328, P99
[7]   Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year [J].
Gross-Goupil, Marine ;
Massard, Christophe ;
Ravaud, Alain .
CURRENT UROLOGY REPORTS, 2012, 13 (01) :16-23
[8]   Methylation of the KEAP1 gene promoter region in human colorectal cancer [J].
Hanada, Naoyuki ;
Takahata, Takenori ;
Zhou, Qiliang ;
Ye, Xulu ;
Sun, Ruowen ;
Itoh, Jugoh ;
Ishiguro, Atsushi ;
Kijima, Hiroshi ;
Mimura, Junsei ;
Itoh, Ken ;
Fukuda, Shinsaku ;
Saijo, Yasuo .
BMC CANCER, 2012, 12
[9]   KEAP1 Genetic Polymorphisms Associate with Breast Cancer Risk and Survival Outcomes [J].
Hartikainen, Jaana M. ;
Tengstrom, Maria ;
Winqvist, Robert ;
Jukkola-Vuorinen, Arja ;
Pylkas, Katri ;
Kosma, Veli-Matti ;
Soini, Ylermi ;
Mannermaa, Arto .
CLINICAL CANCER RESEARCH, 2015, 21 (07) :1591-1601
[10]   Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer [J].
Homma, Shinsuke ;
Ishii, Yukio ;
Morishima, Yuko ;
Yamadori, Tadahiro ;
Matsuno, Yosuke ;
Haraguchi, Norihiro ;
Kikuchi, Norihiro ;
Satoh, Hiroaki ;
Sakamoto, Tohru ;
Hizawa, Nobuyuki ;
Itoh, Ken ;
Yamamoto, Masayuki .
CLINICAL CANCER RESEARCH, 2009, 15 (10) :3423-3432